Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill

It may seem perverse to look for silver linings for the drug industry in the House leaderships “price negotiation” bill. But if you can get past Title 1, the bill reads like an attempt to negotiate with the Senate Finance Committee – and it’s not all bad.

The House Democratic leadership is proposing a $2,000 catastrophic cap in Medicare Part D as part of its year-end push on drug pricing legislation.

That stands out as one proposal in the newly unveiled HR 3 that the pharmaceutical industry could support. While...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet